{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:25:35Z","timestamp":1791548735787,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40121-021-00417-7","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T03:02:46Z","timestamp":1616727766000},"page":"687-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-2479","authenticated-orcid":false,"given":"Helen S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamryn","family":"Plechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Gohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"issue":"10","key":"417_CR1","doi-asserted-by":"publisher","first-page":"e76269","DOI":"10.1371\/journal.pone.0076269","volume":"8","author":"T Abujamel","year":"2013","unstructured":"Abujamel T, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS ONE. 2013;8(10):e76269.","journal-title":"PLoS ONE"},{"issue":"1","key":"417_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.diagmicrobio.2015.05.015","volume":"83","author":"A Adler","year":"2015","unstructured":"Adler A, et al. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole. Diagn Microbiol Infect Dis. 2015;83(1):21\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"417_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1128\/AAC.00090-08","volume":"52","author":"WN Al-Nassir","year":"2008","unstructured":"Al-Nassir WN, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7):2403\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"417_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1017\/ice.2020.277","volume":"41","author":"S Babar","year":"2020","unstructured":"Babar S, et al. Oral vancomycin prophylaxis for the prevention of. Infect Control Hosp Epidemiol. 2020;41(11):1302\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"417_CR5","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/655999","volume":"31","author":"JG Bartlett","year":"2010","unstructured":"Bartlett JG. Detection of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S35-37.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"417_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cid\/cit424","volume":"57","author":"SM Brecher","year":"2013","unstructured":"Brecher SM, et al. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis. 2013;57(8):1175\u201381.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"417_CR7","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1128\/AAC.02176-12","volume":"57","author":"KA Brown","year":"2013","unstructured":"Brown KA, et al. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"417_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1128\/CMR.00016-13","volume":"26","author":"CA Burnham","year":"2013","unstructured":"Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26(3):604\u201330.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"417_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-0039-3400476","volume":"33","author":"KC Carroll","year":"2020","unstructured":"Carroll KC, Mizusawa M. Laboratory Tests for the Diagnosis of Clostridium difficile. Clin Colon Rectal Surg. 2020;33(2):73\u201381.","journal-title":"Clin Colon Rectal Surg"},{"key":"417_CR10","unstructured":"CDC (2019). \"Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC.\""},{"issue":"3","key":"417_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/ice.2018.336","volume":"40","author":"AB Christensen","year":"2019","unstructured":"Christensen AB, et al. Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship study. Infect Control Hosp Epidemiol. 2019;40(3):269\u201375.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 4","key":"417_CR12","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","volume":"22","author":"MJ Crobach","year":"2016","unstructured":"Crobach MJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63-81.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"417_CR13","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/jac\/dkt129","volume":"68","author":"A Deshpande","year":"2013","unstructured":"Deshpande A, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"417_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","volume":"17","author":"KE Dingle","year":"2017","unstructured":"Dingle KE, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"417_CR15","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1093\/cid\/cis335","volume":"55","author":"ER Dubberke","year":"2012","unstructured":"Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88-92.","journal-title":"Clin Infect Dis"},{"key":"417_CR16","doi-asserted-by":"crossref","unstructured":"Dunn, A. N., et al. (2020). \"The impact of clinical decision support alerts on Clostridioides difficile Testing: a systematic review.\" Clin Infect Dis.","DOI":"10.1093\/cid\/ciaa152"},{"issue":"2","key":"417_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.bbmt.2016.11.017","volume":"23","author":"CD Ford","year":"2017","unstructured":"Ford CD, et al. Vancomycin-resistant enterococcus colonization and bacteremia and hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(2):340\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"417_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/cid\/civ539","volume":"61","author":"SK Gohil","year":"2015","unstructured":"Gohil SK, et al. Impact of hospital population case-mix, including poverty, on hospital all-cause and infection-related 30-Day readmission rates. Clin Infect Dis. 2015;61(8):1235\u201343.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"417_CR19","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1128\/AAC.00625-11","volume":"55","author":"EJ Goldstein","year":"2011","unstructured":"Goldstein EJ, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother. 2011;55(11):5194\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"417_CR20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, et al. Trends in U.S. Burden of. N Engl J Med. 2020;382(14):1320\u201330.","journal-title":"N Engl J Med"},{"issue":"10","key":"417_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.ajem.2014.07.015","volume":"32","author":"JP Haran","year":"2014","unstructured":"Haran JP, et al. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home risk of administering IV antibiotics. Am J Emerg Med. 2014;32(10):1195\u20139.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"417_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/tid.12612","volume":"18","author":"M Hefazi","year":"2016","unstructured":"Hefazi M, et al. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016;18(6):913\u201320.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"417_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","volume":"67","author":"MP Hensgens","year":"2012","unstructured":"Hensgens MP, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"417_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1017\/ice.2019.15","volume":"40","author":"HY Hughes","year":"2019","unstructured":"Hughes HY, et al. A retrospective cohort study of antibiotic exposure and vancomycin-resistant Enterococcus recolonization. Infect Control Hosp Epidemiol. 2019;40(4):414\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"417_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/cid\/ciu313","volume":"59","author":"S Johnson","year":"2014","unstructured":"Johnson S, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345\u201354.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"417_CR26","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1017\/ice.2016.210","volume":"37","author":"SG Kelly","year":"2016","unstructured":"Kelly SG, et al. Inappropriate Clostridium difficile Testing and Consequent Overtreatment and Inaccurate Publicly Reported Metrics. Infect Control Hosp Epidemiol. 2016;37(12):1395\u2013400.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"417_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/JCM.02126-16","volume":"55","author":"JH Kwon","year":"2017","unstructured":"Kwon JH, et al. Evaluation of correlation between pretest probability for Clostridium difficile infection and clostridium difficile enzyme immunoassay results. J Clin Microbiol. 2017;55(2):596\u2013605.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"417_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1473-3099(16)30397-8","volume":"17","author":"T Lawes","year":"2017","unstructured":"Lawes T, et al. Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. Lancet Infect Dis. 2017;17(2):194\u2013206.","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"417_CR29","first-page":"2369","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369\u201370.","journal-title":"N Engl J Med"},{"issue":"6","key":"417_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1001\/jamainternmed.2016.0177","volume":"176","author":"Y Longtin","year":"2016","unstructured":"Longtin Y, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of c difficile infections: a quasi-experimental controlled study. JAMA Intern Med. 2016;176(6):796\u2013804.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"417_CR31","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/infdis\/173.5.1292","volume":"173","author":"AD Luber","year":"1996","unstructured":"Luber AD, et al. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. J Infect Dis. 1996;173(5):1292\u20134.","journal-title":"J Infect Dis"},{"issue":"7","key":"417_CR32","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of america (IDSA) and society for healthcare epidemiology of america (SHEA). Clin Infect Dis. 2018;66(7):e1\u201348.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"417_CR33","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1017\/S0950268815003118","volume":"144","author":"JA McKINNELL","year":"2016","unstructured":"McKINNELL JA, et al. Patient-level analysis of incident vancomycin-resistant enterococci colonization and antibiotic days of therapy. Epidemiol Infect. 2016;144(8):1748\u201355.","journal-title":"Epidemiol Infect"},{"issue":"9","key":"417_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cmi.2019.02.002","volume":"25","author":"E Meltzer","year":"2019","unstructured":"Meltzer E, et al. Universal screening for Clostridioides difficile in a tertiary hospital: risk factors for carriage and clinical disease. Clin Microbiol Infect. 2019;25(9):1127\u201332.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"417_CR35","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of america. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"417_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1086\/673144","volume":"34","author":"RW Moehring","year":"2013","unstructured":"Moehring RW, et al. Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol. 2013;34(10):1055\u201361.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 2","key":"417_CR37","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/cis440","volume":"55","author":"MM Nerandzic","year":"2012","unstructured":"Nerandzic MM, et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S121-126.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"417_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/fpd.2013.1648","volume":"11","author":"KN Norman","year":"2014","unstructured":"Norman KN, et al. Comparison of antimicrobial susceptibility among Clostridium difficile isolated from an integrated human and swine population in Texas. Foodborne Pathog Dis. 2014;11(4):257\u201364.","journal-title":"Foodborne Pathog Dis"},{"issue":"7","key":"417_CR39","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1128\/JCM.02250-16","volume":"55","author":"Z Peng","year":"2017","unstructured":"Peng Z, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol. 2017;55(7):1998\u20132008.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"417_CR40","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","volume":"175","author":"CR Polage","year":"2015","unstructured":"Polage CR, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792\u2013801.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"417_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00268-017-4139-8","volume":"42","author":"CM Psoinos","year":"2018","unstructured":"Psoinos CM, et al. post-hospitalization treatment regimen and readmission for C. difficile colitis in medicare beneficiaries. World J Surg. 2018;42(1):246\u201353.","journal-title":"World J Surg"},{"issue":"9","key":"417_CR42","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/496986","volume":"41","author":"J P\u00e9pin","year":"2005","unstructured":"P\u00e9pin J, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254\u201360.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"417_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1017\/ice.2018.32","volume":"39","author":"KA Quan","year":"2018","unstructured":"Quan KA, et al. Reductions in Clostridium difficile infection (CDI) rates using real-time automated clinical criteria verification to enforce appropriate testing. Infect Control Hosp Epidemiol. 2018;39(5):625\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"417_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.20411\/pai.v4i2.327","volume":"4","author":"SN Redmond","year":"2019","unstructured":"Redmond SN, et al. Impact of reduced fluoroquinolone use on. Pathog Immun. 2019;4(2):251\u20139.","journal-title":"Pathog Immun"},{"key":"417_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.anaerobe.2019.102072","volume":"58","author":"S Saha","year":"2019","unstructured":"Saha S, et al. Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis. Anaerobe. 2019;58:35\u201346.","journal-title":"Anaerobe"},{"issue":"4","key":"417_CR46","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/infdis\/172.4.993","volume":"172","author":"DK Shay","year":"1995","unstructured":"Shay DK, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172(4):993\u20131000.","journal-title":"J Infect Dis"},{"issue":"4","key":"417_CR47","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jac\/dkt477","volume":"69","author":"C Slimings","year":"2014","unstructured":"Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"417_CR48","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1128\/AAC.00845-15","volume":"59","author":"DR Snydman","year":"2015","unstructured":"Snydman DR, et al. U.S.-based national sentinel surveillance study for the Epidemiology of Clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin. Antimicrob Agents Chemother. 2015;59(10):6437\u201343.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"417_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"JS Solomkin","year":"2010","unstructured":"Solomkin JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of america. Clin Infect Dis. 2010;50(2):133\u201364.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"417_CR50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1086\/588756","volume":"29","author":"X Song","year":"2008","unstructured":"Song X, et al. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29(9):823\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"417_CR51","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.","journal-title":"Clin Infect Dis"},{"issue":"8358","key":"417_CR52","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","volume":"2","author":"DG Teasley","year":"1983","unstructured":"Teasley DG, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043\u20136.","journal-title":"Lancet"},{"key":"417_CR53","doi-asserted-by":"crossref","unstructured":"Thorpe CM et al. \"U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.\" Antimicrob Agents Chemother 2019;63(7).","DOI":"10.1128\/AAC.00391-19"},{"issue":"5","key":"417_CR54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","volume":"22","author":"C Wenisch","year":"1996","unstructured":"Wenisch C, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22(5):813\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"417_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ajg.2015.22","volume":"110","author":"IM Zacharioudakis","year":"2015","unstructured":"Zacharioudakis IM, et al. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(3):381\u201390.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"417_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1086\/519265","volume":"45","author":"FA Zar","year":"2007","unstructured":"Zar FA, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"417_CR57","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12879-016-1786-6","volume":"16","author":"S Zhang","year":"2016","unstructured":"Zhang S, et al. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447.","journal-title":"BMC Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00417-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T01:38:04Z","timestamp":1666834684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00417-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00417-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"18 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}